In the current study, we investigated the molecular consequences of XRN2 deficiency in lung and breast cancer cells in conjunction with PARP inhibition via Rucaparib and Olaparib to gain mechanistic insights into the synthetic lethality of XRN2 and PARP1. The gene discussed is PARP1; the disease is breast cancer.